Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nectar Lifesciences's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Nectar Lifesciences's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Nectar Lifesciences's highest Yield on Cost was 0.61. The lowest was 0.00. And the median was 0.26.
NSE:NECLIFE's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.34 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Nectar Lifesciences 5-Year Yield-on-Cost % Related Terms
NSE:NECLIFE vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Nectar Lifesciences (NSE:NECLIFE) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nectar Lifesciences and its competitors. According to the industry distribution chart, Nectar Lifesciences ranks #999999 out of 508 companies in the Drug Manufacturers industry.
Is Nectar Lifesciences' 5-Year Yield-on-Cost % too high?
Nectar Lifesciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Nectar Lifesciences ranks #999999 out of 508 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #999999 out of 508 companies for 5-Year Yield-on-Cost %. This places Nectar Lifesciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.34, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Nectar Lifesciences and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nectar Lifesciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹12.31 — trading 79.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Nectar Lifesciences' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued.
The current stock price of ₹12.31 is trading 79.4% above its estimated GF Value™ of ₹6.86.
GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.
Key valuation signals for NSE:NECLIFE:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹6.86 vs. price of ₹12.31 (79.4% above fair value)
No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
46GF Score
Get the complete analysis for NSE:NECLIFE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
